Pralsetinib receives FDA approval for lung cancer with RET gene fusions

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Gavreto (pralsetinib) has received an accelerated approval from FDA for adult patients with metastatic RET fusion-positive non-small cell lung cancer, as detected by an FDA-approved test.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login